Targeting a specific protein to improve prostate cancer treatment
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapy
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11005305
This study is exploring a new way to treat advanced prostate cancer by targeting a protein that helps cancer cells survive damage, and it's designed for patients who haven't responded to current treatments, with the hope of making those treatments work better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11005305 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating prostate cancer by inhibiting a protein called Rev1, which plays a crucial role in helping cancer cells survive DNA damage. The study focuses on patients with advanced prostate cancer who have developed resistance to current therapies. By disrupting the mechanisms that allow cancer cells to tolerate DNA damage, the research aims to enhance the effectiveness of existing treatments. Patients may be monitored for their response to this new therapeutic strategy over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, especially those with BRCA mutations or who have developed resistance to hormonal therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have genetic mutations related to DNA repair may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer, particularly those who have become resistant to current therapies.
How similar studies have performed: Previous research has shown promise in targeting DNA damage response pathways in cancer therapy, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HONG, JIYONG — DUKE UNIVERSITY
- Study coordinator: HONG, JIYONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer